Product Description
A substance being studied in the treatment of melanoma. CHIR-265 may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. It is a type of Raf kinase inhibitor and angiogenesis inhibitor. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chir-265)
Mechanisms of Action: RAFk Inhibitor,VEGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Melanoma
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2007-005367-10 | P2 |
Completed |
Melanoma |
2014-11-18 |
|
| CHIR-265-MEL01 | P2 |
Completed |
Melanoma |
2013-11-01 |
55% |
| CMEK162X2102 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-09-01 |
21% |